

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 December 2024 (26.12.2024)



(10) International Publication Number
WO 2024/263705 A3

- (51) **International Patent Classification:**
C12N 15/86 (2006.01) *B01D 15/26* (2006.01)
- (21) **International Application Number:**
PCT/US2024/034714
- (22) **International Filing Date:**
20 June 2024 (20.06.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|--------------------------------|----|
| 63/522,037 | 20 June 2023 (20.06.2023) | US |
| 63/537,158 | 07 September 2023 (07.09.2023) | US |
| 63/620,672 | 12 January 2024 (12.01.2024) | US |
| 63/654,267 | 31 May 2024 (31.05.2024) | US |
| 63/657,389 | 07 June 2024 (07.06.2024) | US |
| 63/661,425 | 18 June 2024 (18.06.2024) | US |

Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(74) **Agent:** ISACSON, John, P. et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(71) **Applicant:** REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) **Inventors:** THAKUR, Garima; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). MINK, Sheldon, Robert; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). TUSTIAN, Andrew, David; c/o

(54) **Title:** METHODS FOR PURIFYING FILLED ADENO-ASSOCIATED VIRUS CAPSIDS




FIG. 12A

(57) **Abstract:** The inventions provide methods of purifying full adeno-associated virus (AAV) capsids, wherein the method comprises the steps of (a) subjecting a sample comprising AAV capsids in buffer to anion exchange chromatography (AEX) to separate full AAV capsids from capsids that are not full (that is, partially-filled AAV capsids, nearly empty AAV capsids and empty AAV capsids) and form a first pool ("first AEX pass"), wherein the first pool is enriched in the ratio of full capsids to capsids that are not full; and (b) subjecting the first pool to anion exchange chromatography to form a second pool ("second AEX pass"), wherein the second pool is further enriched in the ratio of full capsids to capsids that are not full (that is, partially-filled AAV capsids, nearly empty AAV capsids and empty AAV capsids), wherein the enrichment in full capsids can be least 3 fold. Third, fourth and more AEX passes also can be undertaken. Depth filtration, single-pass tangential flow filtration and affinity exchange also can be included in the inventive methods, preferably undertaken prior to AEX. Enriched AAV preparations and drug products also are provided.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

27 February 2025 (27.02.2025)